Literature DB >> 23817599

Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus.

Atsushi Iwabuchi, Tomohiro Kamoda, Makoto Saito, Hiroki Nozue, Isho Izumi, Takeki Hirano, Ryo Sumazaki.   

Abstract

BACKGROUND: It is poorly understood whether dipeptidyl peptidase 4 (DPP4) activity is altered and how DPP4 contributes to glycemic control in patients with type 1 diabetes mellitus (T1DM). AIM: The aim of this study was to measure serum DPP4 activity and to assess its relationships to metabolic variables in T1DM children.
METHODS: Serum DPP4 activity was determined using a fluorometric assay in 43 T1DM and 26 control children.
RESULTS: Serum DPP4 activity was significantly higher in T1DM children than in controls (3.57 ± 0.99 vs. 2.67 ± 0.77 U/mL, p<0.001). In the T1DM children, DPP4 activity was not correlated with HbA1c, blood glucose, or diabetes duration. A significant negative correlation was found between DPP4 activity and serum adiponectin levels in the T1DM group (r=-0.35, p<0.05).
CONCLUSIONS: Serum DPP4 activity was increased in the T1DM children, whereas it was not associated with glycemic control. Given the negative correlation between serum DPP4 and adiponectin levels, further investigations are warranted to elucidate the role of DPP4 on insulin sensitivity in T1DM children.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817599     DOI: 10.1515/jpem-2013-0122

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  6 in total

1.  Dipeptidyl peptidase-4 activity might be a link between tumour necrosis factor alpha and insulin resistance in type 1 diabetes.

Authors:  Lea Duvnjak; Kristina Blaslov; Matea Nikolac Perković; Jadranka Knežević Ćuća
Journal:  Endocrine       Date:  2016-02-23       Impact factor: 3.633

2.  Dipeptidyl peptidase IV inhibition delays developmental programming of obesity and metabolic disease in male offspring of obese mothers.

Authors:  Kim Ramil C Montaniel; Matthew Bucher; Elysse A Phillips; Cun Li; Elinor L Sullivan; Paul Kievit; Sandra Rugonyi; Peter W Nathanielsz; Alina Maloyan
Journal:  J Dev Orig Health Dis       Date:  2022-01-24       Impact factor: 3.034

Review 3.  Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus.

Authors:  Jaquellyne Gurgel Penaforte-Saboia; Carlos Eduardo Barra Couri; Natasha Vasconcelos Albuquerque; Vanessa Lauanna Lima Silva; Natália Bitar da Cunha Olegario; Virgínia Oliveira Fernandes; Renan Magalhães Montenegro Junior
Journal:  Diabetes Metab Syndr Obes       Date:  2021-02-10       Impact factor: 3.168

Review 4.  Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.

Authors:  Jie Huang; Xinxin Liu; Yingying Wei; Xinlu Li; Shupei Gao; Lingli Dong; Xiaoquan Rao; Jixin Zhong
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

Review 5.  Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis.

Authors:  Kongye Lu; Benli Su; Xiuxiang Meng
Journal:  J Diabetes Res       Date:  2018-09-24       Impact factor: 4.011

6.  Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1.

Authors:  Mithun Kumer Sarker; Jong Han Lee; Dae Ho Lee; Kwang-Hoon Chun; Hee-Sook Jun
Journal:  Aging (Albany NY)       Date:  2020-01-06       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.